Prospective study of the effect of a glucosamine hydrochloride and chondroitin sulfate combination on systemic inflammation parameters in patients with knee osteoarthritis (report 2)
Authors:
- E. A. TaskinaETE. A. Taskina
- E. M. VukailovichEVE. M. Vukailovich
- L. I. AlekseevaLAL. I. Alekseeva
- N. G. KashevarovaNKN. G. Kashevarova
- E. A. StrebkovaESE. A. Strebkova
- N. M. SavushkinaNSN. M. Savushkina
- E. P. SharapovaESE. P. Sharapova
- T. A. KorotkovaTKT. A. Korotkova
- A. S. AvdeevaAAA. S. Avdeeva
- E. Yu. SamarkinaESE. Yu. Samarkina
- M. E. DiatroptovMDM. E. Diatroptov
- S. I. GlukhovaSGS. I. Glukhova
Open Access
- 17 August 2026
- journal article
- Published by IMA Press, LLC in Modern Rheumatology Journal
- Vol. 20 (4) , 67-74
Abstract
Objective: to evaluate the effect of a combination of glucosamine hydrochloride (GH) 500 mg and chondroitin sulfate (CS) 500 mg on systemic inflammation parameters in patients with inflammatory (IP) and metabolic (MP) phenotypes of knee osteoarthritis (OA). Material and methods. At the first stage of the study, which lasted 3 months, the efficacy of Artra® was evaluated in 70 patients with a definite diagnosis of stage II–III knee OA and walking pain ≥4 points on the numerical rating scale (NRS). All patients received Artra® and topical nonsteroidal anti-inflammatory drugs as needed. Changes in NRS pain, the WOMAC index, and patient global health assessment using a visual analog scale were determined. At the second stage of the study, the efficacy of Artra® was analyzed in two patient subgroups: those with the metabolic phenotype of OA (n=29) and those with the inflammatory phenotype of OA (n=12). CRP levels were measured in all patients at visits 1 and 3; in 22 patients, serum concentrations of 17 cytokines, chemokines, and growth factors were also measured at baseline and after 3 months. Results and discussion . After a 3-month course of therapy, a statistically significant (pConclusion . Artra® is characterized by a significant symptomatic effect, including analgesic and anti-inflammatory effects, in patients with the OA phenotypes that are most difficult to treat, namely MP and IP. Our study confirmed the ability of the drug to reduce the production of several proinflammatory cytokines and chemokines that play an important role in the development and progression not only of OA but also of other agerelated diseases, including metabolic syndrome. The findings indicate that the drug can affect different components of OA pathogenesis, which supports its use in patients with comorbidities.Keywords
This publication has 17 references indexed in Scilit:
- A prospective study on the effects of glucosamine hydrochloride and chondroitin sulfate combination on systemic inflammation markers in patients with knee osteoarthritis (report 1)Modern Rheumatology Journal, 2025
- The influence of type 2 diabetes mellitus on clinical manifestations of osteoarthritisModern Rheumatology Journal, 2024
- Symptomatic delayed-acting drugs (SYSADOA): new applicationsModern Rheumatology Journal, 2022
- Early osteoarthritis: development of diagnostic criteriaModern Rheumatology Journal, 2020
- Features of cytokine balance in patients with osteoarthrosis and atherosclerosisSiberian Medical Review, 2020
- Antiresorptive-cytokine effects of the chondroprotective therapy in patients with lower back painS.S. Korsakov Journal of Neurology and Psychiatry, 2020
- The combination of chondroitin sulfate and glucosamine (artra) for pain relief and to reduce the consumption of NSAIDs in patients with I-II stages of osteoarthritis of the kneePirogov Russian Journal of Surgery, 2016
- Accumulation of metabolic risk factors such as overweight, hypertension, dyslipidaemia, and impaired glucose tolerance raises the risk of occurrence and progression of knee osteoarthritis: a 3-year follow-up of the ROAD studyOsteoarthritis and Cartilage, 2012
- Role of immune inflammation in the pathogenesis of osteoarthrosis and possibilities of correction of immune impairmentsModern Rheumatology Journal, 2011
- Perspectives of contained chondroprotective therapy of osteoarthritis. Results of an open randomized study of Artra preparation in patients with gonarthrosisRheumatology Science and Practice, 2004